U.S. Set to Approve Revolutionary Treatment: A Major Breakthrough

The U.S. Food and Drug Administration is expected to approve exa-cel, a gene-editing treatment for sickle cell disease. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, exa-cel would be the first medicine in the U.S. to use CRISPR gene-editing technology. The treatment aims to alleviate the symptoms of sickle cell disease by editing a person’s DNA using CRISPR technology, thereby turning on a protein called fetal hemoglobin to help red blood cells maintain their healthy shape. Approval of exa-cel would be a significant milestone, offering relief to the approximately 100,000 people in the U.S. affected by sickle cell disease.

While the treatment could be a breakthrough for patients, it also presents challenges for the American health-care system. Wall Street anticipates that the treatment could cost around $2 million per patient, and tens of thousands of people could be eligible. Additionally, exa-cel would only be available at specialized health-care facilities, limiting its accessibility. Despite these potential hurdles, exa-cel has shown promising results in clinical trials, with participants experiencing a significant reduction in pain crises. The FDA’s approval of exa-cel would not only provide hope to patients with sickle cell disease but also pave the way for other gene-editing treatments in the future.

Help improve our content system

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

Share this story:

Transplant News
Transplant News

Transplant News brings you the news and content that matters to the transplant community. From patient stories, to the latest in transplant innovation, Transplant News is your window into the world of transplantation.